Article Text
A difficult case
Hypothyroid ataxia complicating monoclonal antibody therapy
Abstract
We present a case of cerebellar dysfunction due to severe hypothyroidism induced by pembrolizumab, a member of the ‘immune checkpoint inhibitor’ class of cancer immunotherapies. Thyroxine replacement completely resolved his symptoms and signs. We also discuss the neurological immune-related complications of checkpoint inhibitors.
- neuroimmunology
- cerebellar ataxia
- neuroendocrinology
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Guillain-Barré syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data
- Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives
- Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
- Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort
- Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
- Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
- Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records
- Cardiotoxicity of immune checkpoint inhibitors
- Investigating hypothyroidism